Tivozanib approved for US patients with refractory advanced RCC
medwireNews: The US FDA has permitted the use of tivozanib for treating advanced renal cell carcinoma (RCC) patients who have received at least two prior lines of therapy.
The VEGFR–tyrosine kinase inhibitor (TKI) was evaluated in the phase 3 TIVO-3 trial, which showed a significant progression-free survival benefit with tivozanib versus sorafenib in the relapsed or refractory setting. The objective response rate was also higher among tivozanib-treated participants, but overall survival was comparable between groups at the time of analysis.
Tivozanib should be administered with or without food at a daily dose of 1.34 mg for 21 days of each 28-day cycle until the patient experiences disease progression or unacceptable toxicity.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group